Jack Szostak, Ph.D.
Moderna Scientific Advisory Board Chairman, 2009 Nobel Prize in Medicine, Howard Hughes Medical Institute Investigator, Professor of Genetics at Harvard Medical School, and Alex Rich Distinguished Investigator, Dept. of Molecular Biology and the Center for Computational and Integrative Biology at Massachusetts General Hospital



Dr. Szostak was appointed chair of the science advisory board in August 2011. He is an Investigator of the Howard Hughes Medical Institute, professor of genetics at Harvard Medical School, and the Alex Rich Distinguished Investigator in the Department of Molecular Biology and the Center for Computational and Integrative Biology at Massachusetts General Hospital. Dr. Szostak’s early research on telomere structure and function, and the role of telomere maintenance in preventing cellular senescence, was recognized by the 2006 Albert Lasker Basic Medical Research Award and the 2009 Nobel Prize in Physiology or Medicine, shared with Drs. Elizabeth Blackburn and Carol Greider. In the 1990s Dr. Szostak and his colleagues developed in vitro selection as a tool for the isolation of functional RNA, DNA, and protein molecules from large pools of random sequences. Dr. Szostak’s current research interests are in the laboratory synthesis of self-replicating systems and the origin of life. Dr. Szostak is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science.


Ulrich H. von Andrian, M.D.
Mallinckrodt Professor of Immunopathology at Harvard Medical School



Ulrich H. von Andrian, MD is the Mallinckrodt Professor of Immunopathology at Harvard Medical School. He received his medical degree from the Ludwig-Maximilians University in Munich, Germany, where he also conducted doctorate research on blood-brain barrier dysfunction following brain injury. In 1989, he joined the La Jolla Institute for Experimental Medicine and UCSD as a postdoctoral fellow working with Dr. Karl-E. Arfors. His postdoctoral research involved the development of intravital microscopy techniques that led to the discovery of the multi-step leukocyte adhesion cascade in vivo. After a second postdoctoral fellowship in the laboratory of Dr. Eugene C. Butcher at Stanford University, Dr. von Andrian joined the faculty of Harvard Medical School in 1994. He was appointed to his current position in 2006. His scientific research is focused on the regulation and function of immune cells in health and disease. To this end, his laboratory employs intravital microscopy techniques combined with other experimental approaches to study the migration, communication, differentiation and function of immune cells in living animals. Dr. von Andrian is a scientific founder of Selecta Biosciences, a biotech company that develops a nanotechnology platform for therapeutic and prophylactic immune modulation.


Michael Diamond, M.D., Ph.D.

Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology, and Head, Division of Infectious Diseases and Vaccine Development Center for Human Immunology and Immunotherapy Programs at Washington University School of Medicine



Michael Diamond, M.D., Ph.D. is the head of the Division of Infectious Disease and Vaccine Development, Center for Human Immunology and Immunotherapy Programs at Washington University School of Medicine. Dr. Diamond joined Washington University in 2001. He received his M.D. and Ph.D. degrees from Harvard Medical School and Harvard University. He completed his post-doctoral training at the University of California, Berkeley, and his internship, residency, and fellowship in infectious diseases at the University of California, San Francisco. His current research focuses on the interface between viral pathogenesis and the host immune response, with an emphasis on mechanisms of innate and adaptive immune control and viral evasion. Seven globally important human pathogens are studied, West Nile encephalitis, Japanese encephalitis virus, Dengue hemorrhagic fever, Zika, Venezuelan equine encephalitis, Chikungunya, and hepatitis C viruses.


Ron Eydelloth, D.V.M., D.A.C.V.P.

President, Nonclinical Development Consulting Services



Dr. Eydelloth is a board certified veterinary pathologist with more than 30 years of experience in pharmaceutical research and development. He received his undergraduate degree from the University of Maryland, a doctorate in veterinary medicine from The Ohio State University, and completed post-doctoral fellowships in comparative medicine and comparative pathology in the Department of Pathology at the Johns Hopkins University School of Medicine. During his career in the pharmaceutical industry, Dr. Eydelloth held senior scientific and managerial positions at Merck Research Laboratories and GlaxoSmithKline; contributed directly to the discovery and development of potential therapies for cardiovascular, metabolic, musculoskeletal, hematologic, neoplastic, gastrointestinal, and central nervous system disorders; and played pivotal roles in the world-wide registration of nine marketed products. Since the establishment of Nonclincial Development Consulting Services in 2009, Dr. Eydelloth has used his expertise to support the research and development objectives of more than 30 pharmaceutical companies and academic laboratories.


Colin R. Gardner, Ph.D.
President, Pharmavue LLC



Dr. Gardner, a native of Scotland, is a veteran Pharmaceutical Company Executive with a background in Physical Chemistry and Chemical Engineering. After post-doctoral experience at Harvard Medical School and MIT, he joined the pharmaceutical industry, initially in Strasbourg, France where he spent 6 years in the Centre de Recherche Merrell International developing a broad experience of the drug development process from Discovery to Product Development. He was recruited to Merck and Co. Inc. in 1981 where he headed a Drug Delivery group before being given the opportunity to build a novel Early Development function to interface with the powerful Merck Discovery organizations located in a number of sites in the US , Canada, Europe and Japan. This new function permitted Merck to re-engineer selection of new drug development candidates by consideration of their “developability”, incorporating the idea that pharmaceutical attributes, in addition to biological properties, are critical to accelerating progress of new chemical entities (NCE) into clinical trials to determine their efficacy, safety and tolerability.

Dr. Gardner was promoted to Global VP for Pharmaceutical Development and was involved in the development and launch of 16 NCEs and three vaccines, many of which were break-through products in the pharmaceutical industry.

Dr. Gardner moved to the Biotech Industry in 2001 when he became the CSO of TransForm Pharmaceuticals which was acquired by Johnson & Johnson in 2005. He remained at the company for four years before retiring and founding Pharmavue LLC, a pharmaceutical development consulting company. He has consulted with over 20 biotech/medical device companies principally in the Cambridge/Boston area and served on the SABs of many of them.


Rachel Green, Ph.D.
Professor of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Howard Hughes Medical Institute Investigator



Rachel Green received her Ph.D. in Biochemistry from Harvard Medical School where she studied RNA and primitive self-replicating systems in Jack Szostak’s lab. These studies relied on the development of in vitro selection approaches that have been broadly used for the analysis of functional RNAs in many systems. Her post-doctoral work was performed in the laboratory of Harry Noller at the University of California, Santa Cruz where she defined ribosomal RNA elements essential for binding the universally conserved CCA-ends of the tRNA to orient these substrates for catalysis. After joining the Department of Molecular Biology and Genetics in 1998, her work has continued to focus on mechanisms of translation in bacteria and eukaryotes and in its regulation. Early work at Hopkins primarily focused on the molecular mechanisms of core events of the translation elongation cycle including tRNA selection, peptide bond formation and translocation. These studies culminated in revealing a novel form of “proofreading” by the bacterial ribosome that occurs following peptide bond formation. More recent work has focused on defining the molecular mechanisms of mRNA surveillance in bacteria and eukaryotes, using a combination of pre-steady state kinetic approaches in in vitro reconstituted systems and the genomic approach called ribosome profiling. Other work in the lab focuses on defining the molecular mechanisms of translational repression by miRNAs and other protein factors. Dr. Green is a member of the National Academy of Sciences.


Robert Langer, Sc.D.
Academic Co-Founder, Moderna; David H. Koch Institute Professor, MIT



Robert S. Langer is the David H. Koch Institute Professor at MIT (there are 14 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer has written more than 1,180 articles. He also has approximately 800 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to more than 250 pharmaceutical, chemical, biotechnology and medical device companies. He is the most cited engineer in history.

He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 to 2002 and as its Chairman from 1999 to 2002.

Dr. Langer has received over 250 major awards including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; the 2008 Millennium Prize, the world’s largest technology prize; and the 2012 Priestley Medal, the highest award of the American Chemical Society. He is the also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008) and the Prince of Asturias Award for Technical and Scientific Research (2008). In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine.” In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.


Sander G. Mills, Ph.D.
Senior Consultant in Medicinal Chemistry and Drug Discovery



Sander G. Mills, Ph.D. is a senior level consultant in medicinal chemistry and drug discovery. After completing his Ph.D. in physical organic chemistry in Professor Peter Beak’s laboratory at the University of Illinois at Urbana/Champaign, he joined the laboratory of Professor Clayton Heathcock at the University of California, Berkeley as an NIH Postdoctoral Fellow, exploring total syntheses of novel alkaloids. From Berkeley he joined the Merck Research Laboratories in Rahway, New Jersey. During a nearly three decade career in this organization, Dr. Mills took on a number of senior level roles, including Head of Rahway Medicinal Chemistry, Head of Global Chemistry, and Vice President and Head of Process Chemistry. His research at Merck was wide-ranging, dealing with the design and synthesis of small molecules to treat asthma, pain, HIV infection, autoimmune diseases, and CNS disorders. Dr. Mills was part of the team that discovered EMEND®, a substance P antagonist for the prevention of chemotherapy-induced nausea and vomiting. He and his group also identified IVEMEND®, a water-soluble prodrug of EMEND® for parenteral administration. Dr. Mills has been an author or co-author on more than 90 papers in professional journals on drug design, synthetic organic chemistry and the biology of medicinally active substances. He has also been an inventor or co-inventor on eighty U.S. patents covering an array of drug candidates and synthetic methods.


Ralph Weissleder, M.D., Ph.D.
Thrall Professor of Radiology and Professor of Systems Biology, Harvard Medical School (HMS)



Dr. Weissleder is a Professor at Harvard Medical School, Director of the Center for Systems Biology at Massachusetts General Hospital (MGH), and Attending Clinician (Interventional Radiology) at MGH. Dr. Weissleder is also a member of the Department of Systems Biology at HMS and the Harvard Cancer Center. Dr. Weissleder’s research interests include the development of novel high resolution molecular imaging systems, tools for early disease detection, new and more advanced nanomaterials for imaging, and modeling methods for systems analysis. Increasingly, his work has been focused on reconciling the gap that exists between traditional cell biology and human biology. His work on imaging, nanomaterials and miniaturized chips has led to a number of new technologies and advanced clinical trials. Dr. Weissleder is currently the principal investigator of several National Institute of Health grants and consortia. He has published over 800 publications in peer reviewed journals and has authored several textbooks. He has received the J. Taylor International Prize in Medicine, the Millennium Pharmaceuticals Innovator Award, the Society for Molecular Imaging Lifetime Achievement Award and is a member of the German National Academy of Sciences (Leopoldina) and of the US National Academies of Medicine.